Characteristic | Total: n = 42 | ||
---|---|---|---|
n | % | ||
Type of neoplasm | Gastrointestinal | 9 | 21.4 |
Breast | 9 | 21.4 | |
Hematological | 6 | 14.3 | |
Gynecological | 4 | 9.5 | |
Lung | 3 | 7.1 | |
Genitourinary | 3 | 7.1 | |
Skin | 3 | 7.1 | |
Head and neck | 2 | 4.8 | |
Non-specific | 3 | 7.1 | |
Decade of initiation | 1980s | 2 | 4.8 |
1990s | 5 | 11.9 | |
2000s | 12 | 28.6 | |
2010s | 23 | 54.8 | |
Study status | Completed | 35 | 83.3 |
Ongoing | 7 | 16.7 | |
Protocol availability | Accessible | 23 | 54.8 |
Inaccessible | 19 | 45.2 | |
Clinical phase | I | 2 | 4.8 |
I/II | 1 | 2.4 | |
II | 9 | 21.4 | |
II/III | 1 | 2.4 | |
III | 7 | 16.7 | |
IV | 1 | 2.4 | |
N/A | 21 | 50.0 | |
Randomization | Randomized | 31 | 73.8 |
Non-randomized | 5 | 11.9 | |
Single-arm | 6 | 14.3 | |
Blinding | Blinded | 2 | 4.8 |
Open-label | 40 | 95.2 | |
Number of study arms | 1 | 6 | 14.3 |
2 | 30 | 71.4 | |
3 or more | 6 | 14.3 | |
Type of intervention | Pharmacotherapy | 24 | 57.1 |
Surgery | 13 | 31.0 | |
Radiotherapy | 16 | 38.1 | |
Other | 7 | 16.7 | |
Combination | 15 | 35.7 | |
Type of comparator | Active | 34 | 81.0 |
Standard of care or equivalent | 28 | 66.7 | |
Placebo | 2 | 4.8 | |
None | 7 | 16.7 | |
Primary endpoint(s) | Overall survival | 6 | 14.3 |
Quality of life | 1 | 2.4 | |
Surrogate | 26 | 61.9 | |
Secondary endpoint(s) | Overall survival | 26 | 61.9 |
Quality of life | 23 | 54.8 | |
Surrogate | 36 | 85.7 | |
Site-level setting | Monocentric | 11 | 26.2 |
Multicentric | 31 | 73.8 | |
Country-level setting | National | 29 | 69.0 |
International | 13 | 31.0 | |
Legal sponsorship | By industry | 3 | 7.1 |
By other party | 39 | 92.9 | |
Funding source | Commercial | 15 | 35.7 |
Non-commercial or academic | 27 | 64.3 | |
 | Median | IQR | |
Study duration (in years) | 5.5 | 3–8 | |
Impact factor journal of publication | 9.162 | 4.853–41.316 | |
Number of participants | Phase II trials | 68 | 51–121 |
Phase III trials | 501 | 231.5–748 | |
Overall | 161 | 87.5–538.5 |